Sign In
Buy REPL
$9.98
+1.11 (+12.51%)
At Close: Jun 03, 2026
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchased
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm
12:47pm, Saturday, 09'th Aug 2025
NEW YORK , Aug. 9, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 an
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”)(NASDAQ: REPL). Such
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options If you purchased or acquir
Shareholders of Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL
04:25pm, Friday, 08'th Aug 2025
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities law
NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL).
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 a
Replimune (REPL) Q1 Loss Widens 61%
12:02pm, Thursday, 07'th Aug 2025
Replimune (REPL) Q1 Loss Widens 61%
Replimune Group: The Prospects For FDA Approval After Rejection
10:08am, Thursday, 07'th Aug 2025
Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in refractory melanoma. The company's pipeline is centered on RP1, making the rece
Shareholders that lost money on Replimune Group, Inc.(REPL) should contact The Gross Law Firm about pending Class Action - REPL
08:45am, Thursday, 07'th Aug 2025
NEW YORK , Aug. 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the cla
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
08:00am, Thursday, 07'th Aug 2025
WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou
